Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAC2.2/VA Therapy for Low-Risk Embryonal Rhabdomyosarcoma
NCT00245089Phase 2Unknown
- Sponsor
- Japan Rhabdomyosarcoma Study Group
- Start
- May 2004
- Primary completion
- Apr 2011
- Modality
- DNA Intercalators/Alkylators, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vincristine, actinomycin D, cyclophosphamide, sponsored by Japan Rhabdomyosarcoma Study Group. Status: unknown.
02
Drugs
vincristineactinomycin Dcyclophosphamide
Beyond the preview
Go deeper on NCT00245089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00245089.